Itraconazole (R 51 211): A clinical review of its antimycotic activity in dermatology, gynecology, and internal medicine

Itraconazole was highly effective in skin infections caused by dermatophytes and yeasts. In addition, vaginal candidosis responded well to oral itraconazole therapy. Treatment periods for superficial mycoses ranged from 2 to 3 days in vaginal infections to up to 2 months in tinea pedis. The daily dose in superficial mycoses ranged from 50 mg to 200 mg (median 100 mg). In systemic mycoses, itraconazole is the first compound active in sporotrichosis since the advent of potassium iodide in 1901. It has also been shown to be active in aspergillosis and chromomycosis in man. The median daily dose of itraconazole administered in systemic mycoses was 100 mg (50–800 mg). The median treatment length in systemic mycoses was 6 months (15 days‐2.5 years).